TABLE OF CONTENTS
1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 OVERVIEW OF NORTH AMERICA AI IN BIOINFORMATICS MARKET 12
1.4 LIMITATIONS 14
1.5 MARKETS COVERED 14
2 MARKET SEGMENTATION 16
2.1 MARKETS COVERED 16
2.2 GEOGRAPHICAL SCOPE 17
2.3 YEARS CONSIDERED FOR THE STUDY 17
2.4 CURRENCY AND PRICING 17
2.5 DBMR TRIPOD DATA VALIDATION MODEL 18
2.6 MULTIVARIATE MODELLING 21
2.7 OFFERING LIFELINE CURVE 22
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 23
2.9 DBMR MARKET POSITION GRID 24
2.10 MARKET SECTOR COVERAGE GRID 25
2.11 VENDOR SHARE ANALYSIS 26
2.12 SECONDARY SOURCES 27
2.13 ASSUMPTIONS 27
3 EXECUTIVE SUMMARY 28
4 PREMIUM INSIGHTS 31
4.1 PESTEL ANALYSIS 32
4.2 PORTER'S FIVE FORCES 33
5 NORTH AMERICA AI IN BIOINFORMATICS MARKET :MARKET OVERVIEW 34
5.1 DRIVERS 36
5.1.1 REDUCTION IN THE GENETIC SEQUENCING COST 36
5.1.2 GROWING DEMAND FOR BIOINFORMATICS 38
5.1.3 INCREASING PUBLIC-PRIVATE SECTOR FUNDING FOR BIOINFORMATICS 38
5.2 RESTRAINTS 39
5.2.1 HIGH COST OF INSTRUMENTATION 39
5.2.2 CYBERSECURITY CONCERNS IN BIOINFORMATICS 40
5.3 OPPORTUNITIES 42
5.3.1 RISE IN HEALTHCARE EXPENDITURE 42
5.3.2 STRATEGIC INITIATIVES BY KEY PLAYERS 43
5.3.3 ADVANCEMENT IN BIOINFORMATICS TECHNOLOGY 44
5.4 CHALLENGES 45
5.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM AI-BASED BIOINFORMATICS TECHNOLOGY 45
5.4.2 CHALLENGES OF IMPLEMENTING BIOINFORMATIC TECHNOLOGY IN THE CLINICAL LAB 46
6 NORTH AMERICA AI IN BIOINFORMATICS MARKET, BY OFFERING 48
6.1 OVERVIEW 49
6.2 SERVICES 52
6.3 SOFTWARE 52
6.4 OTHERS 53
7 NORTH AMERICA AI IN BIOINFORMATICS MARKET, BY TYPE 54
7.1 OVERVIEW 55
7.2 MACHINE LEARNING 58
7.3 DEEP LEARNING 58
7.4 OTHERS 59
8 NORTH AMERICA AI IN BIOINFORMATICS MARKET, BY PRODUCTS AND SERVICES 60
8.1 OVERVIEW 61
8.2 BIOINFORMATICS SERVICES 64
8.2.1 DATA ANALYSIS 64
8.2.2 SEQUENCING SERVICES 65
8.2.3 DATABASE MANAGEMENT 65
8.2.4 OTHERS 65
8.3 BIOINFORMATICS PLATFORMS 65
8.3.1 SEQUENCE ANALYSIS PLATFORMS 66
8.3.2 SEQUENCE ALIGNMENT PLATFORMS 66
8.3.3 STRUCTURAL ANALYSIS PLATFORMS 66
8.3.4 SEQUENCE MANIPULATION PLATFORMS 66
8.3.5 OTHERS 66
8.4 KNOWLEDGE MANAGEMENT TOOLS 67
8.4.1 GENERALIZED KNOWLEDGE MANAGEMENT TOOLS 67
8.4.2 SPECIALIZED KNOWLEDGE MANAGEMENT TOOLS 67
9 NORTH AMERICA AI IN BIOINFORMATICS MARKET, BY APPLICATION 68
9.1 OVERVIEW 69
9.2 GENOMICS 72
9.3 CHEMOINFORMATICS & DRUG DESIGN 72
9.4 PROTEOMICS 73
9.5 DNA SEQUENCING 73
9.6 SYSTEM BIOLOGY 74
9.7 TRANSCRIPTOMICS 74
9.8 TEXT MINING 75
9.9 MICROARRAYS 75
9.10 METABOLOMICS 76
9.11 OTHERS 76
10 NORTH AMERICA AI IN BIOINFORMATICS MARKET, BY SECTOR 77
10.1 OVERVIEW 78
10.2 MEDICAL BIOTECHNOLOGY 81
10.3 ANIMAL BIOTECHNOLOGY 81
10.4 PLANT BIOTECHNOLOGY 82
10.5 ENVIRONMENTAL BIOTECHNOLOGY 82
10.6 FORENSIC BIOTECHNOLOGY 83
10.7 OTHERS 83
11 NORTH AMERICA AI IN BIOINFORMATICS MARKET, BY COUNTRY 84
11.1 U.S. 90
11.2 CANADA 93
11.3 MEXICO 96
12 NORTH AMERICA AI IN BIOINFORMATICS MARKET: COMPANY LANDSCAPE 99
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 99
13 SWOT ANALYSIS 100
14 COMPANY PROFILE 101
14.1 ILLUMINA, INC. 101
14.1.1 COMPANY SNAPSHOT 101
14.1.2 REVENUE ANALYSIS 101
14.1.3 PRODUCT PORTFOLIO 102
14.1.4 RECENT DEVELOPMENTS 102
14.2 DASSAULT SYSTEMES 103
14.2.1 COMPANY SNAPSHOT 103
14.2.2 REVENUE ANALYSIS 103
14.2.3 PRODUCT PORTFOLIO 104
14.2.4 RECENT DEVELOPMENT 104
14.3 EUROFINS SCIENTIFIC 105
14.3.1 COMPANY SNAPSHOT 105
14.3.2 REVENUE ANALYSIS 105
14.3.3 PRODUCT PORTFOLIO 106
14.3.4 RECENT DEVELOPMENT 106
14.4 THERMO FISHER SCIENTIFIC INC. 107
14.4.1 COMPANY SNAPSHOT 107
14.4.2 REVENUE ANALYSIS 107
14.4.3 PRODUCT PORTFOLIO 108
14.4.4 RECENT DEVELOPMENT 108
14.5 QIAGEN 109
14.5.1 COMPANY SNAPSHOT 109
14.5.2 PRODUCT PORTFOLIO 109
14.5.3 RECENT DEVELOPMENT 109
14.6 ARDIGEN 110
14.6.1 COMPANY SNAPSHOT 110
14.6.2 PRODUCT PORTFOLIO 110
14.6.3 RECENT DEVELOPMENT 110
14.7 BIOMAX INFORMATICS AG 111
14.7.1 COMPANY SNAPSHOT 111
14.7.2 PRODUCT PORTFOLIO 111
14.7.3 RECENT DEVELOPMENT 111
14.8 CELBRIDGESCIENCE. 112
14.8.1 COMPANY SNAPSHOT 112
14.8.2 PRODUCT PORTFOLIO 112
14.8.3 RECENT DEVELOPMENTS 112
14.9 DNASTAR 113
14.9.1 COMPANY SNAPSHOT 113
14.9.2 PRODUCT PORTFOLIO 113
14.9.3 RECENT DEVELOPMENT 113
14.10 ELUCIDATA 114
14.10.1 COMPANY SNAPSHOT 114
14.10.2 PRODUCT PORTFOLIO 114
14.10.3 RECENT DEVELOPMENT 114
14.11 INDX. AI. 115
14.11.1 COMPANY SNAPSHOT 115
14.11.2 PRODUCT PORTFOLIO 115
14.11.3 RECENT DEVELOPMENTS 115
14.12 INSILICO MEDICINE 116
14.12.1 COMPANY SNAPSHOT 116
14.12.2 PRODUCT PORTFOLIO 116
14.12.3 RECENT DEVELOPMENTS 116
14.13 JADBIO & GNOSIS DATA ANALYSIS 117
14.13.1 COMPANY SNAPSHOT 117
14.13.2 PRODUCT PORTFOLIO 117
14.13.3 RECENT DEVELOPMENTS 117
14.14 NEOGENOMICS LABORATORIES 118
14.14.1 COMPANY SNAPSHOT 118
14.14.2 REVENUE ANALYSIS 118
14.14.3 PRODUCT PORTFOLIO 119
14.14.4 RECENT DEVELOPMENT 119
14.15 PAIGE AI, INC. 120
14.15.1 COMPANY SNAPSHOT 120
14.15.2 PRODUCT PORTFOLIO 120
14.15.3 RECENT DEVELOPMENT 120
14.16 SOMALOGIC OPERATING CO., INC. 121
14.16.1 COMPANY SNAPSHOT 121
14.16.2 PRODUCT PORTFOLIO 121
14.16.3 RECENT DEVELOPMENT 121
14.17 SOPHIA GENETICS 122
14.17.1 COMPANY SNAPSHOT 122
14.17.2 PRODUCT PORTFOLIO 122
14.17.3 RECENT DEVELOPMENT 122
14.18 SOURCE BIOSCIENCE. 123
14.18.1 COMPANY SNAPSHOT 123
14.18.2 PRODUCT PORTFOLIO 123
14.18.3 RECENT DEVELOPMENT 123
15 QUESTIONNAIRE 124
16 RELATED REPORTS 127

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.